Resistant Hypertension

CHICAGO — In adults with difficult-to-treat and resistant hypertension, firibastat failed to demonstrate efficacy to lower unattended office systolic BP, according to findings from the FRESH trial.

CHICAGO — A radiofrequency renal denervation system lowered BP in patients with resistant hypertension already on antihypertensive medication at 6 months, but did not meet its primary efficacy endpoint.

Transcatheter Cardiovascular Therapeutics, held Sept. 16 to 19 in Boston, featured the latest clinical science in interventional cardiology, as well as forums on innovative technologies, regulatory matters and other topics.

The American Heart Association Scientific Sessions will be held live in Chicago and can be attended virtually Nov. 5 to 7, and will feature nine late-breaking science sessions over 3 days.

LOUISVILLE, Ky. — Various potential treatments for patients with resistant hypertension should come on the market within the next few years, a speaker said during the American Society for Preventive Cardiology Congress on CVD Prevention.

BP reduction at 36 months after renal denervation vs. sham procedure.

Renal denervation therapy is associated with a sustained reduction in BP out to 3 years as well as an improvement in time spent in the recommended BP target range, with registry data showing the results translate to improved CV outcomes.

WASHINGTON — In patients with treatment-resistant hypertension, despite taking one to three BP-lowering medications, radiofrequency renal denervation conferred BP reduction out to 36 months, researchers reported.

Xanthine oxidase and mitochondrial DNA damage-associated molecular patterns may represent novel biomarkers of resistant hypertension among Black patients, researchers reported.

Ultrasound renal denervation in patients with triple-therapy resistant hypertension remained effective at 6 months, according to new data from RADIANCE-HTN TRIO reported at TCT 2021.